Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human AMG 355 alone and with pembrolizumab in advanced solid tumors
jRCT2031240106Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of FPA157 and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more (2 arms), sponsored by Amgen. Primary endpoints: Number of participants who experience a dose-limiting toxicity, Number of participants who experience a treatment-emergent adverse event and 1 more. Started Mar 2024; status: completed.
02
Drugs
FPA157pembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric cancer (GC)melanoma
Beyond the preview
Go deeper on jRCT2031240106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240106.